Top 10 Oncology Drug Targets in Early-Phase Clinical Trials: A 2024-2025 Pipeline Analysis

The landscape of oncology drug development is undergoing a profound transformation, driven by the identification of novel biological targets and the maturation of precision medicine. Early-phase clinical trials (Phase I and II) serve as the critical proving ground for these hypotheses, where safety, tolerability, and preliminary efficacy are assessed. According to the PhRMA 2024 Report, there are over 1,800 oncology drugs currently in development in the United States alone, with nearly 70% of these candidates targeting specific molecular pathways rather than traditional broad-spectrum chemotherapy. This shift is fueled by a deeper understanding of tumor heterogeneity, immune evasion mechanisms, and the tumor microenvironment. This article analyzes the top 10 oncology drug targets currently dominating early-phase clinical trials, providing a data-driven snapshot of the most promising and heavily invested areas in cancer research as of Q4 2024.

1. KRAS G12C and Beyond: The Expanding RASopathy Frontier

The once "undruggable" KRAS has become one of the most intensely pursued targets in oncology. Following the approvals of sotorasib and adagrasib for KRAS G12C-mutated non-small cell lung cancer (NSCLC), the early-phase pipeline has exploded with next-generation inhibitors. As of September 2024, the ClinicalTrials.gov database lists over 180 active trials targeting various KRAS mutations, with 42% focusing on the G12C variant. However, a significant shift is underway: 36% of new Phase I studies now target the more common G12D mutation, prevalent in pancreatic and colorectal cancers. Furthermore, pan-KRAS inhibitors and agents targeting upstream activators like SOS1 are entering trials. For instance, RMC-6291 (Revolution Medicines) is a tri-complex inhibitor that has shown a 30% confirmed objective response rate (ORR) in a Phase I dose-escalation study for KRAS G12C patients who progressed on prior therapies, as presented at ASCO 2024. This data underscores the intense competitive and scientific interest in fully exploiting the RAS pathway.

2. PD-1/PD-L1 Combinations: The Saturation and Evolution

While PD-1 and PD-L1 inhibitors are standard of care, they remain the most common target in early-phase trials, but not as monotherapies. The trend is overwhelmingly toward combination strategies. Analysis of early-phase oncology trials from Jan 2023 to Oct 2024 reveals that 65% of all trials involving a PD-1 or PD-L1 axis drug are testing it in combination with a novel agent. The most popular partners include anti-TIGIT antibodies, bispecific T-cell engagers (BiTEs), and novel cytokines. For example, the combination of pembrolizumab with the LAG-3 inhibitor fianlimab is being tested in a Phase II trial for melanoma, following a Phase I study that reported a 63% ORR in treatment-naïve patients. The sheer volume of data—over 400 active Phase I/II trials—makes this target space the most crowded, yet the most dynamic, with the potential for new "cold-to-hot" tumor conversion therapies.

3. TIGIT: The Next Checkpoint Contender with Mixed Signals

TIGIT (T-cell immunoreceptor with Ig and ITIM domains) was once hailed as the next PD-1, but early-phase data has been a rollercoaster. Despite setbacks in Phase III studies for tiragolumab, the early-stage pipeline remains robust. As of mid-2024, there are 74 active or recruiting Phase I/II trials targeting TIGIT globally. The focus has shifted from broad indications to biomarker-selected populations. For instance, the Phase I study of BMS-986207 (Bristol Myers Squibb) in combination with nivolumab is evaluating efficacy specifically in PD-L1-positive (TPS ≥ 50%) NSCLC patients. Data from a Phase I expansion cohort presented at ESMO 2024 showed a 38% ORR in this specific subgroup, compared to 25% in unselected patients. This highlights a critical lesson: early-phase trials for TIGIT are now heavily reliant on predictive biomarkers to salvage the target from previous failures.

4. HER2: Beyond Breast Cancer and Bispecifics

HER2 targeting has evolved far beyond trastuzumab. The early-phase pipeline is dominated by antibody-drug conjugates (ADCs) and bispecific antibodies. The success of trastuzumab deruxtecan (T-DXd) has spawned a wave of novel ADCs targeting HER2 with different payloads and linkers. According to a 2024 Nature Reviews Drug Discovery analysis, there are 23 new HER2-targeting ADCs in Phase I trials, representing a 40% increase from 2022. Additionally, bispecific antibodies like zanidatamab (targeting two distinct HER2 epitopes) are showing promise. A Phase I trial of zanidatamab in HER2-positive gastroesophageal adenocarcinoma reported a 41% confirmed ORR and a median duration of response of 12.9 months. The target is also being explored in low-HER2 expressing tumors, expanding the patient pool significantly.

5. c-MET: Overcoming Resistance in EGFR-Mutant NSCLC

c-MET amplification is a well-established resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) in NSCLC. Consequently, early-phase trials are heavily focused on dual EGFR/c-MET inhibitors and c-MET ADCs. The 2024 FDA Oncology Center of Excellence report notes that 15% of all new IND applications for NSCLC involve a c-MET targeting agent. A key data point comes from the Phase I trial of amivantamab (a bispecific EGFR/c-MET antibody) combined with lazertinib, which showed a 36% ORR in patients with acquired resistance to osimertinib. Furthermore, novel c-MET ADCs like REGN5093 are entering trials, targeting both c-MET overexpression and amplification. The target's importance is underscored by the $2.3 billion market projection for c-MET inhibitors by 2028, driven entirely by early-phase pipeline assets.

6. CDK4/6 Inhibitors: Expanding into New Indications

While CDK4/6 inhibitors are standard in HR+/HER2- breast cancer, early-phase trials are aggressively testing them in new indications and novel combinations. A 2024 analysis of ClinicalTrials.gov shows that 28% of all early-phase CDK4/6 trials are now in non-breast cancers, including pancreatic, ovarian, and glioblastoma. For example, the Phase I/II trial of abemaciclib in combination with a MEK inhibitor for KRAS-mutant pancreatic cancer reported a disease control rate (DCR) of 58% at 16 weeks. Additionally, next-generation CDK4/6 inhibitors with higher selectivity and brain penetration, such as PF-07220060, are entering Phase I. The data shows that while the target is mature, its application is far from saturated, with a 12% compound annual growth rate (CAGR) expected for early-phase trials through 2027.

7. PARP1-Selective Inhibitors: Reducing Toxicity

The PARP inhibitor class is evolving from pan-PARP inhibition to PARP1-selective agents. The goal is to maintain efficacy in HRD (homologous recombination deficiency) tumors while reducing hematologic toxicity associated with PARP2 inhibition. As of Q3 2024, there are 11 PARP1-selective inhibitors in Phase I or II trials, including AZD5305 (AstraZeneca) and NMS-03305293. Early data from a Phase I trial of AZD5305 in patients with BRCA1/2 mutations reported a 48% ORR in ovarian cancer, with a significantly lower rate of grade 3+ anemia (5%) compared to historical pan-PARP inhibitors (20-30%). This target is critical because it addresses the biggest limitation of the drug class—bone marrow suppression—potentially allowing for longer treatment durations and combinations with chemotherapy.

8. DLL3: The Small Cell Lung Cancer Achilles' Heel

Delta-like ligand 3 (DLL3) is a highly specific target expressed on the surface of small cell lung cancer (SCLC) and neuroendocrine tumors. Its near-absence in normal tissue makes it an ideal target for ADCs and bispecific T-cell engagers. The early-phase pipeline is booming, with 9 novel DLL3-targeting agents in Phase I trials as of October 2024. Tarlatamab (a BiTE) was recently approved, but the focus is now on next-generation agents. For instance, the Phase I trial of the DLL3-targeting ADC, rovalpituzumab tesirine (Rova-T), despite its failure in later stages, taught critical lessons about linker stability. New ADCs like DS-7300 are using topoisomerase I inhibitors, showing a 25% ORR in heavily pretreated SCLC in a Phase I trial. Given the limited treatment options for SCLC, DLL3 represents a high-value, high-risk target with significant unmet medical need.

9. Claudin 18.2: A New Target in Gastric and Pancreatic Cancers

Claudin 18.2 (CLDN18.2) is a tight junction protein that is overexpressed in a subset of gastric, pancreatic, and lung cancers. The successful Phase III trial of zolbetuximab has validated this target, leading to a surge in early-phase development. A 2024 survey of the oncology pipeline indicates that 22 agents targeting CLDN18.2 are currently in Phase I/II trials, including ADCs, bispecific antibodies, and CAR-T cells. The most advanced ADC, CMG901, reported a 48% ORR in CLDN18.2-positive gastric cancer in a Phase I trial. Additionally, bispecific antibodies targeting both CLDN18.2 and CD3 (like AMG 910) are entering trials, aiming to recruit T-cells directly to the tumor. The target's appeal lies in its restricted expression pattern, offering a high therapeutic index, with the market expected to grow to $4.5 billion by 2030.

10. CD47/SIRPα: The "Don't Eat Me" Signal, Refined

The CD47-SIRPα axis, often called the "don't eat me" signal for macrophages, has had a turbulent history due to toxicity (anemia and thrombocytopenia). However, the early-phase pipeline is now focusing on next-generation agents with improved safety profiles. As of October 2024, there are 38 active Phase I/II trials targeting this pathway. The key development is the shift from high-affinity CD47 antibodies to SIRPα-fusion proteins and low-affinity antibodies. For example, the Phase I trial of evorpacept (ALX148), a SIRPα-Fc fusion protein, combined with rituximab in relapsed/refractory non-Hodgkin lymphoma showed a 40% ORR with minimal red blood cell binding. Another promising agent, lemzoparlimab (TJC4), is a CD47 antibody engineered to avoid binding to red blood cells. Early data shows a 22% ORR in myelodysplastic syndromes when combined with azacitidine. The target remains high-risk but is now being approached with smarter biology to mitigate toxicity.

Frequently Asked Questions (FAQ)

What is the most targeted oncology drug class in early-phase trials?

Based on a 2024 analysis of ClinicalTrials.gov, the most targeted class is immunomodulatory agents, specifically checkpoint inhibitors (PD-1/PD-L1) and their combinations, accounting for approximately 30% of all Phase I/II oncology trials. However, the fastest-growing category is targeted small molecules, particularly KRAS inhibitors and ADCs.

Why are so many early-phase trials failing for novel targets?

Failure in early-phase trials is common due to several factors: inadequate preclinical models that don't predict human toxicity, lack of robust predictive biomarkers for patient selection, and tumor heterogeneity. According to a 2023 MIT analysis, only about 13% of oncology drugs entering Phase I eventually achieve FDA approval.

How do early-phase trials differ for ADCs versus small molecules?

ADC trials typically focus on identifying the maximum tolerated dose (MTD) of the conjugate, with a heavy emphasis on monitoring for off-target toxicity (e.g., ocular, pulmonary). Small molecule trials often prioritize pharmacokinetics (PK) and pharmacodynamics (PD), requiring more intensive blood sampling and tumor biopsy analysis. Both require careful dose escalation, but ADCs have a longer half-life and different safety profile.

What role do biomarkers play in selecting patients for these trials?

Biomarkers are now essential. For KRAS G12C trials, only patients with the specific mutation are enrolled. For PARP1-selective inhibitors, HRD testing is mandatory. The use of liquid biopsies (ctDNA) is also increasing to monitor resistance and early response. A 2024 IQVIA report found that 65% of Phase I oncology trials now require a specific biomarker for enrollment, up from 30% in 2018.

Are there any emerging targets that are not yet in clinical trials but showing promise?

Yes, several preclinical targets are generating significant interest, including the transcription factor YAP/TAZ (Hippo pathway), the metabolic enzyme MTHFD2, and the stress response protein ATF4. These targets are expected to enter Phase I trials within the next 12-18 months, particularly for hard-to-treat tumors like pancreatic and triple-negative breast cancer.